Desocodeine

Desocodeine
Names
IUPAC name
3-Methoxy-17-methyl-4,5α-epoxymorphinan
Systematic IUPAC name
(4R,4aR,7aS,12bS)-9-Methoxy-3-methyl-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline
Other names
Dihydrodeoxycodeine
Identifiers
3D model (JSmol)
ChemSpider
UNII
  • InChI=1S/C18H23NO2/c1-19-9-8-18-12-4-3-5-15(18)21-17-14(20-2)7-6-11(16(17)18)10-13(12)19/h6-7,12-13,15H,3-5,8-10H2,1-2H3/t12-,13+,15-,18+/m0/s1
    Key: ZJWPQUSUXBOTPF-SCGCMHLBSA-N
  • InChI=1/C18H23NO2/c1-19-9-8-18-12-4-3-5-15(18)21-17-14(20-2)7-6-11(16(17)18)10-13(12)19/h6-7,12-13,15H,3-5,8-10H2,1-2H3/t12-,13+,15-,18+/m0/s1
    Key: ZJWPQUSUXBOTPF-SCGCMHLBBV
  • O(c2c1O[C@@H]5[C@@]34c1c(cc2)C[C@@H](N(CC3)C)[C@@H]4CCC5)C
Properties
C18H23NO2
Molar mass 285.387 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Desocodeine is a potent semi-synthetic opioid which is the penultimate intermediate in the manufacture of desomorphine from codeine.[1][2] Desocodeine is a potent analgesic, being as potent as morphine. It is partially metabolized into desomorphine, among others, after parenteral and oral administration.[3][4]

Since 1936, desocodeine has been classified in the US as a Schedule I controlled substance under the Controlled Substances Act, indicating that the FDA has determined that there are no legal medicinal uses for it.[5]

In Canada, desocodeine is classified as a Schedule I drug under the Controlled Drugs and Substances Act.


Synthesis of desomorphine from codeine

References

  1. ^ PubChem. "Desocodeine". pubchem.ncbi.nlm.nih.gov. Retrieved 2022-11-15.
  2. ^ "Desocodeine | C18H23NO2 | ChemSpider". www.chemspider.com. Retrieved 2022-11-15.
  3. ^ Eddy NB (1 November 1935). "STUDIES OF MORPHINE, CODEINE AND THEIR DERIVATIVES X. DESOXYMORPHINE-C, DESOXYCODEINE-C AND THEIR HYDROGENATED DERIVATIVES". Journal of Pharmacology and Experimental Therapeutics. 55 (1): 257–267. S2CID 93217792.
  4. ^ Himmelsbach Clifton K (1939). "STUDIES OF CERTAIN ADDICTION CHARACTERISTICS OF (a) DIHYDROMORPHINE ("PARAMORPHAN"), (b) DIHYDRODESOXYMORPHINE-D ("DESOMORPHINE"), (c) DIHYDRODESOXYCODEINE-D ("DESOCODEINE"), AND (d) METHYLDIHYDROMORPHINONE ("METOPON")". Journal of Pharmacology and Experimental Therapeutics. 67: 239–249. S2CID 102042333.
  5. ^ "DEA Diversion Control Division". Archived from the original on 4 March 2016. Retrieved 4 May 2015.



Stub icon

This analgesic-related article is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.